The exercise period for warrants in Scandion Oncology A/S begins today
Today, September 10[th], 2020, marks the beginning of the exercise period for the warrants of series TO 1 that were issued in connection with Scandion Oncology A/S (“Scandion Oncology” or “the Company”) issue of units during June 2019. The exercise period runs until and including October 1[st], 2020. Upon full exercise of all warrants, Scandion Oncology will be allocated approximately SEK 12.4 million (before costs). Sedermera Fondkommission is the financial adviser and Markets & Corporate Law Nordic AB is the legal adviser in connection with the warrant exercise.Scandion Oncology issued